Skip to main navigation menu Skip to main content Skip to site footer
Academia Open

Medicine

Vol 7 (2022): December

Achievements and Prospects of Treatment of Chronic Gastritis
Pencapaian dan Prospek Pengobatan Gastritis Kronis



(*) Corresponding Author
DOI
https://doi.org/10.21070/acopen.7.2022.5716
Published
January 12, 2023

Abstract

This article presents a comprehensive examination of the influence of genetic factors on individual drug response in pharmacotherapy, emphasizing the potential for personalized medicine and minimizing the risk of adverse drug reactions. The study aims to explore the goals, methods, results, and implications of incorporating modern approaches to personalized pharmacotherapy. By understanding the role of genetics in drug response, physicians and researchers can envision improved methods of tailoring treatments to individual patients, ultimately reducing the likelihood of side effects and optimizing therapeutic outcomes. This article highlights the promising prospects of personification of pharmacotherapy, highlighting the potential for revolutionizing medical practice and enhancing patient care.

Highlights:

  • Influence of genetic factors: This article examines the significant impact of genetic factors on an individual's response to drugs in pharmacotherapy, highlighting the importance of understanding genetic variations for personalized treatment.
  • Personalized medicine potential: The study explores the potential for personalized pharmacotherapy, aiming to tailor drug treatments based on an individual's genetic profile, with the goal of minimizing side effects and optimizing therapeutic outcomes.
  • Enhancing patient care: By considering genetic factors, healthcare professionals can anticipate a reduction in adverse drug reactions and improve treatment effectiveness, leading to enhanced patient care and better treatment outcomes.

Keywords: Genetic factors, personalized pharmacotherapy, individual drug response, side effects, treatment outcomes.

References

  1. Isakov, V.A. Farmakogeneticheskiy analiz metabolizma i klinicheskoy effektivnosti ingibitorov protonnogo nasosa/ V.A.Isakov//Klin. farmakol. ter. 2003. № 1. S. 32 - 37.
  2. Kitaeva E. YU., Shprax V.V., Mirzaev K.B., Rijikova K.A., Shuev G.N., Sozaeva J.A., Pimenova YU.A., Kogay V.V., Sechev D.A.// Chastota polimorfizmov genov CYP2C19 i ABCB1, assotsiirovannix s izmeneniem antiagregantnogo deystviya klopidogrela, u russkix i buryat. Sibirskoe meditsinskoe obozrenie. 2018 №3 43-50 S.
  3. Ochilov A.K., G.S.Ochilova. “Znachenie gena CYP2C19 v farmakoterapii pri xronicheskix gastritax» Problemi biologii i meditsini, 2019, № 4 (113)
  4. Ochilov A.K., Musaeva D.M. “Lechenie xronicheskogo gastrita v zavisimosti ot allelnix variantov gena CYP2C19» Mejdunarodnoy nauno- prakticheskoy onlayn- konferensii «Aktualnie voprosi meditsinskoy nauki v XXI veke» g.Tashkent, 25.04.2019g.
  5. Ochilov A.K., Ochilova G.S. Klinichekaya znachimost polimorfizmov gena CYP2C19 // Universitetskaya nauka: vzglyad v buduщee. Sbornik nauchnix trudov po materialam Mejdunarodnoy nauchnoy konferensii, posvyaщennoy 85-letiyu Kurskogo gosudarstvennogo meditsinskogo universiteta (7 fevralya 2020 goda) Tom I. 2020. 376-379 S.
  6. Klichova F.K., Ochilova G.S. Sbornik tezisov II Vserossiyskoy nauchno- prakticheskoy konferensii s mejdunarodnim uchastiem. Bezopasnost farmakoterapii: NOLI NOCERE! g. Kazan, 16 maya 2019 g.
  7. Musaeva D.M., Ochilova G.S. “Znachenie gena MDR-1 v farmakoterapii pri xronicheskix gastritax» Problemi biologii i meditsini, 2019, № 4 (113)
  8. Musaeva D.M., Ochilova G.S. “Surunkali gastritni davolashda MDR-1 allel variantlarining ahamiyati» Materiali mejdunarodnoy nauchno- prakticheskoy onlayn-konferensii «Aktualnie voprosi meditsinskoy nauki v XXI veke» g.Tashkent, 25.04.2019g.
  9. Musaeva D.M., Ochilova G.S. “Surunkali gastritni davolashda MDR-1 allel variantlarining ahamiyati» Materiali mejdunarodnoy nauchno- prakticheskoy onlayn-konferensii «Aktualnie voprosi meditsinskoy nauki v XXI veke» g.Tashkent, 25.04.2019g.
  10. Musaeva D.M., Ochilov A.K., Ochilova G.S. Korreksiya farmakometaboliziruyushey funksii pecheni antioksidantami //Dostijeniya nauki i obrazovaniya. – 2018. – №. 10 (32).
  11. Musaeva D. M., Klichova F. K., Ochilova G. S. Vliyanie GAMK-mimetikov na farmakodinamiku etaminala natriya pri eksperimentalnom toksicheskom gepatite //Nauchniy jurnal. – 2018. – №. 8 (31).
  12. Musaeva D. M., Samadov B. SH., Ochilova G. S. Gepatoprotektornoe vliyanie fenobarbitala pri eksperimentalnom toksicheskom gepatite. 341-344 s.
  13. Ochilov A.K., Musaeva D.M. Osobennosti gena CYP2S19 dlya induvidualizitsii farmakoterapii. //Noviy den v meditsine 1 (29) 2020. 65-68 s.
  14. Ochilova G. S., Musaeva D. M. Vliyanie polimarfizma gena MDR-1 na effektivnost lecheniya xronicheskogo gastrita. //Noviy den v meditsine 1 (29) 2020. 309-312 s.
  15. Arvanitidis, K. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population // К. Arvanitidis, G. Ragia, M. Iordanidou et al.//Fundam. Clin. Pharmacol. 2007. Vol. 21 №4. P. 419 - 426.
  16. Arvanitidis, K. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population // К. Arvanitidis, G. Ragia, M. Iordanidou et al.//Fundam. Clin. Pharmacol. 2007. Vol. 21 №4. P. 419 - 426.
  17. Efrén Martínez-Quintana, Fayna Rodríguez-González, José María Medina-Gil, Paloma Garay-Sánchez, Antonio Tugores // Actividad de CYP2C19 y factores de riesgo cardiovascular en pacientes con síndrome coronario agudo. Medicina Clínica. Volume 149. Issue 6. 2017. Pages 235-239.
  18. Kim K.A., Park P.W., Park J.Y. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects//Br. J. Clin.Pharmacol. 2007, Jan. Vol.63, №1. P. 53–58.
  19. Kim R. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab. Rev., 2012, 34, 47-54.
  20. Kuzuya T., Kobayashi T., Moriyama N., Nagasaka T., Yokoyama I., Uchida K., Nakao A., Nabeshima T. Amlodipine, but not MDR1polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients//Transplantation. 2003. Vol.76, №5.P. 865–868.

Downloads

Download data is not yet available.